Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia

American Journal of Psychiatry

Volumn 174, Issue 10, 2017, Pages 990-998

  Wimberley, Theresa ^a,b,c,d   MacCabe, James H ^a,b,c,d   Laursen, Thomas M ^a,b,c,d   Sørensen, Holger J ^a,b,c,d   Astrup, Aske ^a,b,c,d   Horsdal, Henriette T ^a,b,c,d   Gasse, Christiane ^a,b,c,d   Støvring, Henrik ^a,b,c,d  

^a AARHUS UNIVERSITY   (Denmark)

^b H LUNDBECK A S   (Denmark)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ALL CAUSE MORTALITY; ARTICLE; AUTOMUTILATION; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; POPULATION RESEARCH; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT-RESISTANT SCHIZOPHRENIA; ADOLESCENT; CAUSE OF DEATH; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SCHIZOPHRENIA; SELF-INJURIOUS BEHAVIOR; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CAUSE OF DEATH; CLOZAPINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SCHIZOPHRENIA; SELF-INJURIOUS BEHAVIOR; YOUNG ADULT;

EID: 85031108204     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2017.16091097     Document Type: Article

References (34)

1. Sørensen HJ, Foldager L, Røge R, et al: An association between autumn birth and clozapine treatment in patients with schizophrenia: a population-based analysis. Nord J Psychiatry 2014; 68:428-432
2. National Institute for Health and Clinical Excellence (NICE): Psychosis and Schizophrenia in Adults: Treatment and Management: NICE Clinical Guideline 178. London, NICE, 2014. guidance.nice. org.uk/cg178
3. Scottish Intercollegiate Guidelines Network (SIGN): Management of Schizophrenia: SIGN Publication 131. Edinburgh, SIGN, 2013. http://www.sign.ac.uk/assets/sign131.pdf
4. Fink-Jensen A, Rasmussen I, Viuff AG, et al: Behandlingsvejledning for medicinsk behandling af psykotiske tilstande hos voksne [Treatment Guideline for Medical Treatment of Psychotic States in Adults]. Copenhagen, Denmark, Radet for Anvendelse af Dyr Sygehusmedicin (RADS) [Council for Application of Expensive Hospital Medication], 2016
5. Remington G, Lee J, Agid O, et al: Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use. Expert Opin Drug Saf 2016; 15:1193-1203
6. Beck K, McCutcheon R, Bloomfield MA, et al: The practical management of refractory schizophrenia-the Maudsley Treatment REview and Assessment Team service approach. Acta Psychiatr Scand 2014; 130:427-438
7. Thompson JV, Clark JM, Legge SE, et al: Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders. J Psychopharmacol 2016; 30:436-443
8. Laursen TM, Nordentoft M, Mortensen PB: Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014; 10:425-448
9. Laursen TM: Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res 2011; 131:101-104
10. Tiihonen J, Lönnqvist J, Wahlbeck K, et al: 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374:620-627
11. Kiviniemi M, Suvisaari J, Koivumaa-Honkanen H, et al: Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up. Schizophr Res 2013; 150:274-280
12. Hayes RD, Downs J, Chang CK, et al: The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull 2015; 41:644-655
13. Walker AM, Lanza LL, Arellano F, et al: Mortality in current and former users of clozapine. Epidemiology 1997; 8:671-677
14. Ringbäck Weitoft G, Berglund M, Lindström EA, et al: Mortality, attempted suicide, re-hospitalisation and prescription refill for clozapine and other antipsychotics in Sweden-a register-based study. Pharmacoepidemiol Drug Saf 2014; 23:290-298
15. Stroup TS, Gerhard T, Crystal S, et al: Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. Am J Psychiatry 2016; 173:166-173
16. Meltzer HY, Alphs L, Green AI, et al: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60:82-91
17. Patchan KM, Richardson C, Vyas G, et al: The risk of suicide after clozapine discontinuation: cause for concern. Ann Clin Psychiatry 2015; 27:253-256
18. Kildemoes HW, Sørensen HT, Hallas J: The Danish National Prescription Registry. Scand J Public Health 2011; 39(suppl):38-41
19. Lynge E, Sandegaard JL, Rebolj M: The Danish National Patient Register. Scand J Public Health 2011; 39(suppl):30-33
20. Mors O, Perto GP, Mortensen PB: The Danish Psychiatric Central Research Register. Scand J Public Health 2011; 39(suppl):54-57
21. Pedersen CB: The Danish Civil Registration System. Scand J Public Health 2011; 39(suppl):22-25
22. Helweg-Larsen K: The Danish Register of Causes of Death. Scand J Public Health 2011; 39(suppl):26-29
23. Wimberley T, Støvring H, Sørensen HJ, et al: Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry 2016; 3:358-366
24. Nordentoft M, Wahlbeck K, Hällgren J, et al: Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden. PLoS One 2013; 8:e55176
25. Webb RT, Antonsen S, Mok PL, et al: National cohort study of suicidality and violent criminality among Danish immigrants. PLoS One 2015; 10:e0131915
26. Madsen T, Agerbo E, Mortensen PB, et al: Deliberate self-harm before psychiatric admission and risk of suicide: survival in a Danish national cohort. Soc Psychiatry Psychiatr Epidemiol 2013; 48: 1481-1489
27. Reuter Morthorst B, Soegaard B, Nordentoft M, et al: Incidence rates of deliberate self-harm in Denmark 1994-2011. Crisis 2016; 37:256-264
28. Helweg-Larsen K: Suicide in Denmark [in Danish]. Copenhagen, Denmark, National Institute of Public Health, 2005
29. Thygesen SK, Christiansen CF, Christensen S, et al: The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 2011; 11:83
30. Wang SV, Gagne JJ, Glynn RJ, et al: Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations. Epidemiology 2013; 24:375-378
31. Taylor DM, Douglas-Hall P, Olofinjana B, et al: Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. Br J Psychiatry 2009; 194:165-167
32. Legge SE, Hamshere M, Hayes RD, et al: Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophr Res 2016; 174:113-119
33. Misawa F, Kishimoto T, Hagi K, et al: Safety and tolerability of longacting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res 2016; 176:220-230
34. Ali MS, Groenwold RH, Belitser SV, et al: Methodological comparison of marginal structural model, time-varying Cox regression, and propensity score methods: the example of antidepressant use and the risk of hip fracture. Pharmacoepidemiol Drug Saf 2016; 25 (suppl 1):114-121